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Prion diseases are transmissible, fatal
neurodegenerative diseases affecting
animals and humans (1). The proto-
typical human prion disease, sporadic
Creutzfeldt-Jakob disease (sCJD), is
thought to originate in the CNS, and
no significant accumulation of the
infectious agent (the prion) is found
in extracerebral compartments. This
may be one of the reasons why
human-to-human transmission of
sCJD has been essentially confined to
neurosurgery, tissue transplants, or,
before the advent of recombinant
DNA technology, injection of cadav-
eric pituitary hormones.
The bovine spongiform encepha-
lopathy (BSE) epizootic, however, has
spurred many additional concerns (2).
BSE is clearly transmissible to
humans, and 109 Europeans have — at
the time of writing — already suc-
cumbed to the human counterpart to
BSE, which is called variant
Creutzfeldt-Jakob disease (vCJD) (3).
Unlike sCJD, BSE prions need to find
their way to the CNS, which is the only
organ system in which they can pro-
duce damage. The process by which
prions migrate from the site of inocu-
lation (e.g., the gastrointestinal
[GI]tract) to the CNS is called neu-
roinvasion and represents a crucial
step in the pathogenesis of most natu-
rally occurring prion diseases.
A detailed understanding of the cells
and the molecules responsible for neu-
roinvasion is of utmost importance for
public health, since an arguably large
fraction of the European population
may have been exposed to BSE prions
in the last 15 years. Moreover, pre-
sumptive rate-limiting steps, if they
exist, are likely to represent gratifying
targets for postexposure prophylaxis,
i.e., for interventions aimed at pre-
venting the clinical outbreak of the
disease in persons who have been
exposed to BSE prions.
Stages of neuroinvasion
Some of the players in prion neuroin-
vasion have already been identified.
The march of prions through the
body appears to occur in two steps,
the first of which could be named
lymphoinvasion, while the latter rep-
resents neuroinvasion proper (Figure
1). While the very first step, the pas-
sage through the GI mucosal barrier,
has not yet been studied in much
detail, it has become clear that prions
exploit various components of the
immune system to move around the
body. Both lymphoinvasion and neu-
roinvasion depend on the presence of
B lymphocytes (4). Because expression
of the cellular prion protein by B cells
is not required for neuroinvasion (5),
it has been proposed that their main
function is to enable maintenance of
follicular dendritic cells (FDCs) by
providing lymphotoxin-β to spleen
and lymph nodes. Indeed, suppres-
sion of lymphotoxin-β signaling with
a soluble receptor impairs peripheral
prion pathogenesis (6). Docking of
prions to FDCs is facilitated by com-
plement factors and complement
receptors, suggesting that prions may
be opsonized (7).
In contrast to our relatively well-
developed description of prion replica-
tion in lymphoreticular organs, we
know far less about the rest of the trip
to the CNS. Orally administered prions
can apparently reach the brain via the
parasympathetic vagal nerve (8). How-
ever, more indirect paths also exist and
may represent the more significant
route from the gut to the brain. Thus,
following intraperitoneal delivery of
prions, disease can be delayed by sym-
pathectomy or can be accelerated by
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Figure 1
Some cellular and molecular aspects of
prion neuroinvasion. Prion diseases such
as scrapie manifest as afflictions of the
central nervous system. After being taken
up orally, prions must cross the epithelial
barrier of the gut, probably via gastroin-
testinal M cells (14). Thereafter, en route
to the brain, they colonize several organ
systems, taking advantage of multiple cell
types to effect neuroinvasion. The experi-
ments reported by Aucouturier and col-
leagues (12) indicate that dendritic cells
(DCs) (but also lymphoid cells) isolated
from spleens of prion-infected mice can
induce disease when injected intravenous-
ly into immunodeficient Rag-1–/– mice,
suggesting a possible DC-dependent route
to neuroinvasion. Other possible roles of
dendritic cells in this disease pathway are
discussed in the text.
Could prions access the brain by still
other means? Hematogenic spread is a
possibility worth thinking about, since
BSE appears to be transmissible sheep-
to-sheep by transfusion (10), and sev-
eral plasma proteins bind prions (11).
In the present issue of JCI, Aucouturi-
er and colleagues (12) have investigat-
ed whether CD11c+ dendritic cells
(DCs) may participate in neuroinva-
sion. DCs are distinct from FDCs: the
latter are stromal components of lym-
phoreticular organs, which are not of
hematopoietic origin and, despite the
similarity in their names, have nothing
in common with DCs — a point of
some confusion, even in the published
literature on this topic (13). While DCs
are professional antigen-presenting
cells (APCs), FDCs retain antigens on
their surface via FcγR and complement
receptors, but they do not appear to
process antigens, as APCs do.
Potential pathogenic roles for DCs
in scrapie
Aucouturier and colleagues (12) show
that isolated DCs from scrapie-infect-
ed mice induce disease when injected
intravenously in B- and T-cell deficient
Rag-1–/– mice. Their carefully con-
trolled, extensive experiments certain-
ly place DCs on the prion pathogenesis
map and show that direct injection of
infected cells into the bloodstream can
induce prion disease, bypassing a
requirement for lymphoinvasion.
However, some concerns remain to be
addressed before concluding that DCs
carry prions to the brain in the course
of natural prion infections. For one
thing, Rag-1–/– mice are not deficient in
DCs, yet they are largely protected
from peripherally administered prions,
indicating that the endogenous pool of
DCs does not support neuroinvasion.
Therefore, DCs (not unlike B cells) may
be necessary but not sufficient for neu-
roinvasion. In addition, the crucial
question of whether depletion of DCs
protects host animals from scrapie
must still be addressed if one is to
assess the relative contribution of DCs
to peripheral prion pathogenesis.
Finally, the authors report that intra-
venous injection of other prion-infect-
ed mononuclear cell types also leads to
scrapie in Rag-1–/– mice, a finding that
casts some doubts on the specificity of
DC-triggered pathogenesis.
Despite these concerns, DCs have
been and remain attractive candidates
for several prion transport phenomena,
including transfer of prions from the
basal aspect of mucosal cells (M cells in
Figure 1) to Peyer’s patches (Figure 1).
DCs may well be involved in intranodal
trafficking of prions, e.g., from FDCs to
sympathetic endings. It will be interest-
ing to determine whether expression of
the endogenous prion protein, PrPC, is
required in this process. Given that
PrPC-expressing hematopoietic cells
appear to enhance prion pathogenesis
(14), it will be interesting to study
whether DCs prepared from Prnp–/– ani-
mals will be compromised in their abil-
ity to traffic prions to the CNS, relative
to Prnp+/+ DCs. If the situation modeled
by Aucouturier and colleagues (12),
lymphoreticular organ-independent
spread of prions from the site of entry
to the brain, proves to be significant
outside of a laboratory setting, manip-
ulation of DCs may indeed add to the
growing list of treatments available to
arrest the clinical outbreak of vCJD.
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